Money is pouring in to a hot new area of science that could change the way we think about ageing. Venture capital investors are pouring money in to regenerative medicine. According to a report from Goldman Sachs, venture capital in companies pursuing regenerative medicine has increased from $296 million in 2011to $807 million in 2016, growing roughly 34% year-over-year.